Related coverage linked through entity extraction aliases.
Nov 28, 2025
The FDA approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for prevention of motion-induced vomiting on December 30, 2025. The approval marks the first new pharmacologic treatment for motion sickness in over four decades.
Feb 18, 2026
The European Commission has authorized a new 7.2 mg once-weekly dose of Wegovy (semaglutide) for adults with obesity across all 27 EU member states, following positive opinion from the EMA's scientific committee in December 2025.
Feb 18, 2026
Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
Feb 17, 2026
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Feb 17, 2026
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
Feb 16, 2026
Eli Lilly has stockpiled $1.5 billion in inventory for Orforglipron ahead of an expected FDA decision in April. The oral weight-loss pill aims to compete with Novo Nordisk's recently approved oral Wegovy.
Feb 16, 2026
Researchers used a machine-learning tool to analyze 500,000 UK Biobank participants, providing the first population-scale evidence that insulin resistance is a risk factor for 12 types of cancer.
Feb 16, 2026
Health and Human Services Secretary Robert F. Kennedy Jr. announced the FDA will act on a petition to revoke GRAS status for dozens of processed sweeteners and starches, including corn syrup, unless companies prove they are safe.
Feb 16, 2026
HHS Secretary Robert F. Kennedy Jr. announced the FDA will consider a petition to revoke GRAS status for dozens of processed sweeteners and starches, though he stopped short of promising new regulations on ultraprocessed foods.
Feb 15, 2026
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025, with successful phase 3 trials for cancer drug Jaypirca, next-gen obesity medicine retatrutide, and oral GLP-1 orforglipron, while Alzheimer's drug Kisunla showed cognitive decline benefits.
Feb 14, 2026
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
Feb 15, 2026
The FDA will consider revoking safety exemptions for ultra-processed foods including corn syrup, while retatrutide, a triple-receptor weight loss drug, advances through phase three clinical trials without yet receiving regulatory approval.
Feb 14, 2026
Investigation reveals prescription-only weight-loss drugs Mounjaro and Wegovy are easily accessible in India without proper medical oversight, as semaglutide goes off-patent next month with prices expected to drop 70 percent.
Feb 14, 2026
Novo Nordisk confronts rising generic threats to its semaglutide-based drugs while navigating FDA scrutiny and legal challenges. The company advances oral semaglutide into pediatric diabetes care as competitors prepare to launch imitations.
Feb 14, 2026
Multiple Indian drugmakers begin selling generic versions of Ozempic and Wegovy following March patent expiration, with prices 50-60% below branded counterparts. The launches signal global pricing shifts as Novo Nordisk faces patent losses across multiple markets.
Feb 14, 2026
A Philadelphia jury found Johnson & Johnson liable for a woman's ovarian cancer death linked to talc-based baby powder, awarding $250,000 in damages. The verdict marks the first plaintiffs' win in Philadelphia's talc mass tort litigation.
Feb 14, 2026
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Feb 14, 2026
Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial for injectable VK2735 and plans to advance oral VK2735 into Phase 3, while also filing an IND for a new amylin agonist program targeting obesity.
Feb 14, 2026
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Feb 13, 2026
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
